Pulse Biosciences Inc (PLSE) Quote

PLSE 10Q due March 14

PLSE 10Q due March 7

Taking off after Thursday's earnings phone call!

#PLSE Recent insider transactions: https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/ownership?blueprint=2299718

$PLSE article: Insiders own %57 of o/s (55% owned by Robert Duggan, 2% by other insiders). Institutions own 6.7%.
https://finance.yahoo.com/news/pulse-biosciences-inc-nasdaq-plse-122414850.html?.tsrc=rss

85% chance predicted yesterday for a move higher:
https://tickeron.com/ticker/PLSE/
$PLSE

Tickeron on Twitter (17.8k followers) posts:
$PLSE's Aroon indicator reaches into Uptrend on January 11, 2023. View odds for this and other indicators: https://t.co/rb3VuLqkuK #PulseBiosciences #stockmarket #stock pic.twitter.com/i1VoiqtqoA— Tickeron (@Tickeron) January 12, 2023
$PLSE

SYD on Twitter posts potential to fill to $4.70's. $PLSE: $PLSE nice vcp contraction then breakout. above sma200. potential gap fill around 4.70s pic.twitter.com/MGacthBt1P— 許文龍 (@chft_500) January 10, 2023

Nice moves last couple days.

Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia
September 26 2022 - 08:00AM
Business Wire
Alert
Print
Share On Facebook
Additional 510(k) clearance recently received for use of larger spot size treatment tips with the CellFX System

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company developing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its CellFX System, expanding the indication for use to include the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-III. This specific indication clearance enhances the CellFX System’s general indication FDA clearance and enables the Company to support clinics in marketing and promoting CellFX treatments specifically for patients with sebaceous hyperplasia. The clearance was based on clinical data from the Company’s IDE approved study for the treatment of sebaceous hyperplasia.

The Company also recently received FDA 510(k) clearance of two additional treatment tips with larger spot sizes, specifically 7.5mm and 10mm tip sizes, for treating larger benign lesions. These treatment tips broaden the portfolio of previously available 1.5mm, 2.5mm and 5.0mm treatment tip sizes.

“We are pleased with the continued advancement of the CellFX System and its capabilities to enhance its value proposition for patients, clinicians and any potential commercial partner. These clearances provide further validation of the system’s strong safety and effectiveness profile,” said Kevin Danahy, President and Chief Executive Officer of Pulse Biosciences. “We would like to thank all of the investigators, the staff at their clinics and the patients who participated in these trials, as well as the FDA for their ongoing collaboration as we endeavor to offer the benefits of NPS technology to more patients.”

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX® System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of conditions for which an optimal solution remains unfulfilled. The Company is actively pursuing application development in cardiology, oncology, gastroenterology, and other medical specialties. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. Visit www.pulsebiosciences.com to learn more.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse

$VERI -$4.70 3rd leg down @ $23.80 in @ $23.85 tight SL

INOV up 20% > https://ih.advfn.com/p.php?pid=nmona&article=75627253

SWEET ALERT= https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134517877


CONGRAT$

Someone dumped 100k shares down to @ $11s caused the short circuit. Sub $10 is a good bet maybe although it was starting to bounce of the $11's to the $12.50 before the short circuit kicked in.

I am hoping that means FDA approval is close.

Insider buying.

Pulse Biosciences, Inc (NASDAQ:PLSE) Director Maky Zanganeh acquired 28,790 shares of the business's stock in a transaction dated Thursday, August 3rd. The shares were bought at an average price of $23.96 per share, for a total transaction of $689,808.40. Following the completion of the acquisition, the director now owns 287,225 shares in the company, valued at $6,881,911. The acquisition was disclosed in a legal filing with the SEC.

Director Maky Zanganeh bought 8,290 shares of Pulse Biosciences stock in a transaction dated Wednesday, August 2nd.

Pulse Biosciences, Inc (NASDAQ:PLSE) major shareholder Robert W. Duggan acquired 277,450 shares of Pulse Biosciences stock in a transaction on Thursday, August 3rd. The stock was acquired at an average price of $23.14 per share, with a total value of $6,420,193.00. Following the purchase, the insider now directly owns 3,153,234 shares in the company, valued at $72,965,834.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Insider buying.

Pulse Biosciences, Inc (NASDAQ:PLSE) Director Maky Zanganeh acquired 28,790 shares of the business's stock in a transaction dated Thursday, August 3rd. The shares were bought at an average price of $23.96 per share, for a total transaction of $689,808.40. Following the completion of the acquisition, the director now owns 287,225 shares in the company, valued at $6,881,911. The acquisition was disclosed in a legal filing with the SEC.

Director Maky Zanganeh bought 8,290 shares of Pulse Biosciences stock in a transaction dated Wednesday, August 2nd.

Pulse Biosciences, Inc (NASDAQ:PLSE) major shareholder Robert W. Duggan acquired 277,450 shares of Pulse Biosciences stock in a transaction on Thursday, August 3rd. The stock was acquired at an average price of $23.14 per share, with a total value of $6,420,193.00. Following the purchase, the insider now directly owns 3,153,234 shares in the company, valued at $72,965,834.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

What's happening with this stick now?? Sheesh!

Looking great here

It's coming boom time for Bio Electronic sector



$ENDV
$PLSE

3DYOGI,,, You're absolutely right! PLSE has a market cap 23.5 times that of ENDV & will at some point probably need to pay license fees for ENDV patents.

Yes, ENDV is further along & if it had a market cap of 330 million like PLSE it would be trading @ $1.50

Not bad when you consider ENDV is currently trading @ .065

ENDV further along than Pulse CEO has spent half his sparky buying open shares at an average price of .26 he now owns over 20 million shares insiders own over 40 million on 85 million floating

PLSE 360 million market cap
ENDV 14 million market cap

Loving this stock from 17.34 17.35, sold 90% @ 20.50 pre market last week and I'm an idiot..........

Bullish. In at 19.20

PLSE bullish 19.94









normal chart




log chart